SRTA
Strata Critical Medical, Inc. · Healthcare · Medical - Care Facilities
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 1 | +1 | 16.12K | $72,070 | +1 | n/a |
| Q2 2026 | 64 | +2 | 30.62M | $161.23M | +5 | −4 |
| Q1 2026 | 65 | -1 | 35.82M | $149.75M | +2 | −3 |
| Q4 2025 | 66 | -2 | 36.14M | $173.84M | n/a | −2 |
| Q3 2025 | 16 | +1 | 24.58M | $124.36M | +2 | −1 |
| Q2 2025 | 12 | +1 | 20.26M | $81.63M | +1 | n/a |
| Q1 2025 | 8 | -1 | 12.11M | $33.06M | n/a | −1 |
| Q4 2024 | 9 | 0 | 12.82M | $54.49M | n/a | n/a |
| Q3 2024 | 8 | +1 | 9.76M | $28.71M | +1 | n/a |
| Q2 2024 | 7 | n/a | 8.74M | $30.43M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | ARK Investment Management ✦ | 6.44M | n/a | $22.42M | 0.2% | n/c | 1 | SEC ↗ |
| 2 | Geode Capital Management ✦ (passive) | 1.32M | n/a | $4.60M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 3 | AQR Capital Management ✦ | 546.63K | n/a | $1.90M | 0.0% | n/c | 1 | SEC ↗ ×3 |
| 4 | Renaissance Technologies ✦ | 291.30K | n/a | $1.01M | 0.0% | n/c | 1 | SEC ↗ |
| 5 | Millennium Management ✦ | 94.58K | n/a | $329,128 | 0.0% | n/c | 1 | SEC ↗ |
| 6 | Citadel Advisors ✦ | 25.31K | n/a | $88,065 | 0.0% | n/c | 1 | SEC ↗ |
| 7 | T. Rowe Price ✦ | 19.38K | n/a | $68,000 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 125 holders, 55.49M shares, $231.60M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Director · 5.09K sh · $29,273
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology
5.8% of class · View original SEC filing ↗